ANNX
Annexon, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.23
+1.44%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$4.18
From 52W high−39.22%
Volume4.93M
Market cap$801.92M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$4.18
From 52W high
−39.22%
Volume
4.93M
Market cap
$801.92M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.1x
P/E (TTM)
—
RSI (14)
35.0
MomentumView details →
1D Return
+1.44%
YTD Return
−17.43%
SummaryUpdated Jun 1, 2026
Annexon, Inc. (NASDAQ:ANNX) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in Brisbane, California. The company went public in July 2020 and focuses on discovering and developing novel therapeutics that target the complement system, a critical component of the immune system. Annexon's approach centers on inhibiting C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic disorders where excessive complement activation contributes to disease progression.
Similar companies
Latest newsMore news →
Annexon granted equity inducement awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved on September 12, 2026, per Nasdaq Listing Rule 5635(c)(4).4d agoAnnexon, Inc. reported its Q2 2026 financial results, with a net loss of $55.3 million and diluted EPS of -$0.28, and cash and investments of $209.2 million as of June 30, 2026.40d ago